Lupus (SLE)



Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: Standard of Care
Sponsor:   AstraZeneca
Recruiting


Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus


Condition:   Lupus Erythematosus, Discoid
Interventions:   Device: Pulsed-dye Laser;   Device: Sham
Sponsor:   Chulalongkorn University
Recruiting


Aurinia Renal Response in Active Lupus With Voclosporin


Condition:   Lupus Nephritis
Interventions:   Drug: Voclosporin;   Drug: Placebo Oral Capsule
Sponsor:   Aurinia Pharmaceuticals Inc.
Recruiting


Lupus and Observance


Condition:   Systemic Lupus, Skin Lupus
Intervention:   Biological: Hydroxychloroquine dosage
Sponsor:   University Hospital Center of Martinique
Not yet recruiting


High Quality Evidence of Chinese Lupus Nephritis (HELP)


Condition:   Lupus Nephritis
Intervention:   Other: No Intervention
Sponsor:   Sun Yat-sen University
Recruiting


Walk With Ease Program For Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: "Walk With Ease"
Sponsors:   University of North Carolina, Chapel Hill;   North Carolina Translational and Clinical Sciences Institute
Recruiting


Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis


Condition:   Lupus Nephritis
Interventions:   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
Sponsor:   The University of Hong Kong
Recruiting


Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: BT063;   Biological: Placebo
Sponsor:   Biotest
Active, not recruiting


Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis


Condition:   Lupus Nephritis
Interventions:   Biological: Anifrolumab;   Drug: Placebo
Sponsors:   AstraZeneca;   Parexel
Recruiting


Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Brentuximab vedotin;   Drug: Placebo
Sponsor:   Seattle Genetics, Inc.
Terminated


Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: ACT-334441;   Drug: Placebo
Sponsor:   Actelion
Completed


Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsor:   Northwell Health
Recruiting


Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: MT-1303 Low dose;   Drug: MT-1303 High dose
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed


A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: CC-220;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting


Nelfinavir in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Nelfinavir
Sponsors:   Northwell Health;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting


Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Gardasil
Sponsors:   Wayne State University;   Merck Sharp & Dohme Corp.
Unknown status


Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus


Condition:   Cutaneous Lupus Erythematosus
Intervention:  
Sponsor:   University of Pennsylvania
Recruiting


Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus


Condition:   Subacute Cutaneous Lupus Erythematosus
Interventions:   Drug: KRP203 - 1.2mg;   Drug: Placebo to KRP203 - 1.2 mg
Sponsor:   Novartis Pharmaceuticals
Completed


Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients


Condition:   Discoid Lupus Erythematosus
Intervention:   Drug: CC-10004
Sponsors:   New York University School of Medicine;   Celgene Corporation
Completed


Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis


Condition:   Lupus Nephritis
Intervention:   Drug: NKT-01
Sponsor:   Nippon Kayaku Co.,Ltd.
Completed


A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02


Condition:   Systemic Lupus Erythematosus
Intervention:   Biological: Belimumab
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Completed


Duke Lupus Registry


Conditions:   Systemic Lupus Erythematosus;   Cutaneous Lupus
Intervention:  
Sponsor:   Duke University
Recruiting


A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g


Condition:   Lupus Nephritis
Intervention:   Drug: Rituximab
Sponsor:   Genentech, Inc.
Withdrawn


Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Biological: Hematopoietic stem cell transplantation
Sponsor:   Northwestern University
Active, not recruiting


Lupus Genetics Studies


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsors:   Oklahoma Medical Research Foundation;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Refine Your Search Advanced Search